These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Mouse model of pulmonary cavitary tuberculosis and expression of matrix metalloproteinase-9. Ordonez AA; Tasneen R; Pokkali S; Xu Z; Converse PJ; Klunk MH; Mollura DJ; Nuermberger EL; Jain SK Dis Model Mech; 2016 Jul; 9(7):779-88. PubMed ID: 27482816 [TBL] [Abstract][Full Text] [Related]
3. Risk factors for pulmonary cavitation in tuberculosis patients from China. Zhang L; Pang Y; Yu X; Wang Y; Lu J; Gao M; Huang H; Zhao Y Emerg Microbes Infect; 2016 Oct; 5(10):e110. PubMed ID: 27729644 [TBL] [Abstract][Full Text] [Related]
4. Tuberculosis, pulmonary cavitation, and matrix metalloproteinases. Ong CW; Elkington PT; Friedland JS Am J Respir Crit Care Med; 2014 Jul; 190(1):9-18. PubMed ID: 24713029 [TBL] [Abstract][Full Text] [Related]
5. [Residual cavitary changes in the lungs in tuberculosis]. PilipchukNS ; Golanov VS Sov Med; 1989; (12):71-4. PubMed ID: 2631255 [No Abstract] [Full Text] [Related]
7. [Outcome of pulmonary tuberculosis with single destructive cavity depending on its size]. Smirnov GA; Ravdel' GD; Fattakhova RM; TrofimovaRI ; Valiev RSh Probl Tuberk; 1990; (2):26-9. PubMed ID: 2345739 [TBL] [Abstract][Full Text] [Related]
8. Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization. Strydom N; Gupta SV; Fox WS; Via LE; Bang H; Lee M; Eum S; Shim T; Barry CE; Zimmerman M; Dartois V; Savic RM PLoS Med; 2019 Apr; 16(4):e1002773. PubMed ID: 30939136 [TBL] [Abstract][Full Text] [Related]
9. High-throughput phenogenotyping Stanley S; Spaulding CN; Liu Q; Chase MR; Ha DTM; Thai PVK; Lan NH; Thu DDA; Quang NL; Brown J; Hicks ND; Wang X; Marin M; Howard NC; Vickers AJ; Karpinski WM; Chao MC; Farhat MR; Caws M; Dunstan SJ; Thuong NTT; Fortune SM bioRxiv; 2023 Apr; ():. PubMed ID: 37090677 [TBL] [Abstract][Full Text] [Related]
18. [Results of treatment in patients with destructive pulmonary tuberculosis without consideration of drug sensitivity in Mycobacterium tuberculosis]. Abashev IM; Kozlova AI; Ivanova LN Probl Tuberk Bolezn Legk; 2008; (1):33-5. PubMed ID: 18318228 [TBL] [Abstract][Full Text] [Related]
19. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Dartois V Nat Rev Microbiol; 2014 Mar; 12(3):159-67. PubMed ID: 24487820 [TBL] [Abstract][Full Text] [Related]
20. Correlates of treatment outcomes and drug resistance among pulmonary tuberculosis patients attending tertiary care hospitals of Kolkata, India. Goswami A; Chakraborty U; Mahapatra T; Mahapatra S; Mukherjee T; Das S; Das A; Dey SK; Ray S; Bhattacharya B; Pal NK PLoS One; 2014; 9(10):e109563. PubMed ID: 25289974 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]